UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: The Swedish specialty pharmaceutical company Orexo AB (STO:ORX) today announce a major change in the competitive landscape for Zubsolv™, its treatment of opioid dependence, which has been submitted and currently is undergoing review at the FDA. Reckitt Benckiser Ltd announced this morning a voluntary discontinuation of the supply of Suboxone® tablets in United States, which currently account for approximately 35% of the US market.
